The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
This paper gives a short review on cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease (AD), from early developments to high-precision validated assays on fully automated lab analyzers. We also discuss developments on novel biomarkers, such as synaptic proteins and Aβ oligomers. Our vision for the future is that assaying a set of biomarkers in a single CSF tube can monitor the whole spectrum of AD molecular pathogenic events. CSF biomarkers will have a central position not only for clinical diagnosis, but also for the understanding of the sequence of molecular events in the pathogenic process underlying AD and as tools to monitor the effects of novel drug candidates targeting these different mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Self-citationBlennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Self-citationSynapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376 · cited 2×
“In 2011, similar, but not identical, criteria for MCI due to AD (Albert et al., 2011) and dementia due to AD (McKhann et al., 2011) were published by the National Institute on Aging— Alzheimer’s Association (NIA-AA) workgroups on diagnostic guidelines for AD.”
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationHansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · cited 3×
“REVIEW published: 29 September 2015 doi: 10.3389/fnins.2015.00345 Frontiers in Neuroscience | www.frontiersin.org 1 September 2015 | Volume 9 | Article 345 Edited by: Sylvain Lehmann,”
InfluentialSelf-citationKnopman, D. S., DeKosky, S. T., Cummings, J. L., Chui, H., Corey–Bloom, J., Relkin, N., Small, G. W., Miller, B., & Stevens, J. C. (2001) · Neurology · doi:10.1212/wnl.56.9.1143 · Cited by 1,410
CSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291 · cited 1×
“The following years, many research reports consistently showed that the “AD profile” of increased CSF levels of T-tau and P-tau together with decreased Aβ42 had high sensitivity and specificity, both in the range of 85–90%, to identify AD dementia, for review see (Blennow and Hampel, 2003).”
Self-citationInverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246 · cited 12×
“Even if CSF Aβ40 is relatively unchanged in AD, the CSF Aβ42/Aβ40 has been suggested to have stronger diagnostic accuracy for AD compared to CSF Aβ42 alone (Hansson et al., 2007).”
InfluentialHuman ApoE isoforms differentially regulate brain amyloid-β peptide clearance
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,242 · cited 1×
“Some studies on mice found that the ApoE isoforms differentially regulates Aβ clearance, and suggested that the APOE genotype contribute to AD risk by differentially regulating clearance of Aβ the brain throughout life (Castellano et al., 2011; Verghese et al., 2013).”
CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176
Jin, M., Shepardson, N., Yang, T., Chen, G., Walsh, D., & Selkoe, D. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017033108 · Cited by 876 · cited 1×
“…has put focus on soluble oligomers of Aβ that may inhibit long-term potentiation (LTP) and cause tau hyperphosphorylation and neuritic dystrophy (Walsh et al., 2002; Jin et al., 2011), possibly by specifically affecting synapses and disturbing synaptic signaling pathways (Pozueta et al., 2013).”
Georganopoulou, D. G., Chang, L., Nam, J.-M., Thaxton, C. S., Mufson, E. J., Klein, W. L., & Mirkin, C. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409336102 · Cited by 835
Blennow, K., Wallin, A., Ågren, H., Spenger, C., Siegfried, J., & Vanmechelen, E. (1995) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815140 · Cited by 789
Self-citationThirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses
Bertram, L., & Tanzi, R. E. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2494 · Cited by 747 · cited 2×
“The Putative APOE Dependence of CSF Aβ42 The apolipoprotein E (APOE) ε4 allele is the main genetic risk factor for AD (Bertram and Tanzi, 2008).”
Improved discrimination of AD patients using β-amyloid (1-42) and tau levels in CSF
Hulstaert, F., Blennow, K., Ivanoiu, A., Schoonderwaldt, H. C., Riemenschneider, M., Deyn, P. P. D., Bancher, C., Cras, P., Wiltfang, J., Mehta, P. D., et al. (1999) · Neurology · doi:10.1212/wnl.52.8.1555 · Cited by 724 · cited 2×
“In the late 1990ies, several studies reported that AD patients possessing the APOE ε4 allele had lower CSF Aβ42 than those without this gene variant (Galasko et al., 1998; Hulstaert et al., 1999).”
Self-citationAltered expression of synaptic proteins occurs early during progression of Alzheimer's disease
Masliah, E., Mallory, M., Alford, M., DeTeresa, R., Hansen, L. A., McKeel, D. W., & Morris, J. C. (2001) · Neurology · doi:10.1212/wnl.56.1.127 · Cited by 720
Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease
Motter, R., Vigo‐Pelfrey, C., Kholodenko, D., Barbour, R., Johnson‐Wood, K., Galasko, D., Chang, L., Miller, B., Clark, C., Green, R., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380413 · Cited by 701 · cited 2×
“…started in 1995 with a series of publications on enzyme-linked immunosorbent assays (ELISA) based on monoclonal antibodies to measure CSF levels of total tau (T-tau) and phosphorylated tau (P-tau) and the 42 amino acid isoform (Aβ42) of β-amyloid (Blennow et al., 1995; Motter et al., 1995).”
Buchhave, P. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.155 · Cited by 664
Andreasen, N., Hesse, C., Davidsson, P., Minthon, L., Wallin, A., Winblad, B., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (1999) · Archives of Neurology · doi:10.1001/archneur.56.6.673 · Cited by 660
Self-citationVisser, P. J., Verhey, F., Knol, D. L., Scheltens, P., Wahlund, L.-O., Freund-Levi, Y., Tsolaki, M., Minthon, L., Wallin, Å. K., Hampel, H., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70139-5 · Cited by 614
Self-citationSZE, C.-I., TRONCOSO, J. C., KAWAS, C., MOUTION, P., PRICE, D. L., & MARTIN, L. J. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199708000-00011 · Cited by 562 · cited 2×
“In 2011, similar, but not identical, criteria for MCI due to AD (Albert et al., 2011) and dementia due to AD (McKhann et al., 2011) were published by the National Institute on Aging— Alzheimer’s Association (NIA-AA) workgroups on diagnostic guidelines for AD.”
Verghese, P. B., Castellano, J. M., Garai, K., Wang, Y., Jiang, H., Shah, A., Bu, G., Frieden, C., & Holtzman, D. M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220484110 · Cited by 556
Amyloid biomarkers in Alzheimer's disease
Blennow, K., Mattsson, N., Schöll, M., Hansson, O., & Zetterberg, H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.03.002 · Cited by 470 · cited 2×
“In 2006, the first study showed that high amyloid ligand retention on amyloid PET almost completely corresponds to low CSF Aβ42 (Fagan et al., 2006), and vice versa, a finding that has been verified in numerous subsequent studies, for review see Blennow et al. (2015).”
Self-citationGalasko, D., Chang, L., Motter, R., Clark, C. M., Kaye, J., Knopman, D., Thomas, R., Kholodenko, D., Schenk, D., Lieberburg, I., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.7.937 · Cited by 442
Klyubin, I., Betts, V., Welzel, A. T., Blennow, K., Zetterberg, H., Wallin, A., Lemere, C. A., Cullen, W. K., Peng, Y., Wisniewski, T., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5161-07.2008 · Cited by 321 · cited 1×
“Aβ oligomers, ranging from dimers, trimers, dodecamers, and larger molecular weight species have been found to be present in CSF (Klyubin et al., 2008; Handoko et al., 2013).”
Self-citationHigh‐molecular‐weight β‐amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients
Fukumoto, H., Tokuda, T., Kasai, T., Ishigami, N., Hidaka, H., Kondo, M., Allsop, D., & Nakagawa, M. (2010) · The FASEB Journal · doi:10.1096/fj.09-150359 · Cited by 264
Portelius, E., Westman-Brinkmalm, A., Zetterberg, H., & Blennow, K. (2006) · Journal of Proteome Research · doi:10.1021/pr050475v · Cited by 206 · cited 1×
“Except for Aβ42, the CSF contains several other Aβ isoforms, the most abundant variant being Aβ40 (Portelius et al., 2006).”
Self-citationNeurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease
Thorsell, A., Bjerke, M., Gobom, J., Brunhage, E., Vanmechelen, E., Andreasen, N., Hansson, O., Minthon, L., Zetterberg, H., & Blennow, K. (2010) · Brain Research · doi:10.1016/j.brainres.2010.09.073 · Cited by 204 · cited 2×
“…got a more central role, together with amyloid PET, due to their high diagnostic performance (Hansson et al., 2006; Li et al., 2007; Brys et al., 2009; Snider et al., 2009; van Rossum et al., 2012), while downstream topographical AD biomarkers, such as volumetric MRI and FDG- PET, were…”
Self-citationInjury markers predict time to dementia in subjects with MCI and amyloid pathology
van Rossum, I. A., Vos, S. J. B., Burns, L., Knol, D. L., Scheltens, P., Soininen, H., Wahlund, L.-O., Hampel, H., Tsolaki, M., Minthon, L., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182704056 · Cited by 136 · cited 1×
“…with amyloid PET, due to their high diagnostic performance (Hansson et al., 2006; Li et al., 2007; Brys et al., 2009; Snider et al., 2009; van Rossum et al., 2012), while downstream topographical AD biomarkers, such as volumetric MRI and FDG- PET, were judged to function better in monitoring…”
Self-citationAPOE ε4 allele is associated with reduced cerebrospinal fluid levels of Aβ42
Prince, J. A., Zetterberg, H., Andreasen, N., Marcusson, J., & Blennow, K. (2004) · Neurology · doi:10.1212/01.wnl.0000128088.08695.05 · Cited by 128 · cited 1×
“This association is present also in cognitively normal elderly (Prince et al., 2004).”
Self-citationAβ40 Oligomers Identified as a Potential Biomarker for the Diagnosis of Alzheimer's Disease
Gao, C. M., Yam, A. Y., Wang, X., Magdangal, E., Salisbury, C., Peretz, D., Zuckermann, R. N., Connolly, M. D., Hansson, O., Minthon, L., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015725 · Cited by 105 · cited 2×
“…such as fluorescence correlation spectroscopy (Pitschke et al., 1998), biobarcode assay (Georganopoulou et al., 2005), misfolded protein assay (Gao et al., 2010), ELISA with the same monoclonal antibody both for capture and detection (Fukumoto et al., 2010), flow cytometry based assays…”
Amyloid-β Oligomers Relate to Cognitive Decline in Alzheimer's Disease
Jongbloed, W., Bruggink, K. A., Kester, M. I., Visser, P.-J., Scheltens, P., Blankenstein, M. A., Verbeek, M. M., Teunissen, C. E., & Veerhuis, R. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-142136 · Cited by 68
Cited by
Gut microbiome alterations in Alzheimer’s disease
Vogt, N. M., Kerby, R. L., Dill-McFarland, K. A., Harding, S. J., Merluzzi, A. P., Johnson, S. C., Carlsson, C. M., Asthana, S., Zetterberg, H., Blennow, K., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-13601-y · Cited by 2,137
Self-citationThe Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade
Cline, E. N., Bicca, M. A., Viola, K. L., & Klein, W. L. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179941 · Cited by 870
The gut microbiota-derived metabolite trimethylamine N-oxide is elevated in Alzheimer’s disease
Vogt, N. M., Romano, K. A., Darst, B. F., Engelman, C. D., Johnson, S. C., Carlsson, C. M., Asthana, S., Blennow, K., Zetterberg, H., Bendlin, B. B., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0451-2 · Cited by 471
Self-citationNeuronal exosomes reveal Alzheimer's disease biomarkers in Down syndrome
Hamlett, E. D., Goetzl, E. J., Ledreux, A., Vasilevko, V., Boger, H. A., LaRosa, A., Clark, D., Carroll, S. L., Carmona‐Iragui, M., Fortea, J., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.08.012 · Cited by 129
Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer’s Dementia: Findings in Two Cohorts
Lue, L.-F., Sabbagh, M. N., Chiu, M.-J., Jing, N., Snyder, N. L., Schmitz, C., Guerra, A., Belden, C. M., Chen, T.-F., Yang, C.-C., et al. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00226 · Cited by 105
Metadata
- Authors
- Blennow, K., & Zetterberg, H.
- Venue
- Frontiers in Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2015-09-29
- Volume
- 9
- Pages
- 345-345
- ISSN
- 1662-453X (ISSN-L)
- OpenAlex
- W1876307764
- Cited by
- 76
- References
- 32
- FWCI
- 10.76
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.